Valuation: vTv Therapeutics Inc.

Market Cap 409M 351M 327M 300M 565M 39.06B 574M 3.86B 1.51B 19.59B 1.53B 1.5B 64.78B P/E 2026 *
-14.6x
P/E 2027 * -8.31x
Enterprise Value 409M 351M 327M 300M 565M 39.06B 574M 3.86B 1.51B 19.59B 1.53B 1.5B 64.78B EV / Sales 2026 *
15.7x
EV / Sales 2027 * -
Free-Float
61.17%
Yield 2026 *
-
Yield 2027 * -
1 day+4.49%
1 week+3.51%
Current month+1.68%
1 month+0.05%
3 months-9.85%
6 months-6.84%
Current year-17.74%
1 week 28.76
Extreme 28.7579
33.2
1 month 28.76
Extreme 28.7579
36.52
Current year 28.75
Extreme 28.75
44
1 year 14.55
Extreme 14.55
44
3 years 7.38
Extreme 7.38
44
5 years 7.38
Extreme 7.38
86.8
10 years 7.38
Extreme 7.38
336
Manager TitleAgeSince
Chief Executive Officer 68 2022-07-31
Director of Finance/CFO 50 2025-05-18
Chief Tech/Sci/R&D Officer - 2023-11-01
Director TitleAgeSince
Director/Board Member 56 2020-11-15
Director/Board Member 48 2022-07-10
Chairman 68 2024-02-29
Date Insider Type Main position Quantity % Market Cap.
6/26/26 Free

Director

6,000 0.1523%
2/17/26 Free

Chief Financial Officer

44,969 1.1419%
2/17/26 Free

Chief Executive Officer

140,000 3.5551%
Change 5-day change 1-year change 3-year change Capi.($)
+4.49%+3.51%+111.97%+22.52% 391M
-1.90%+3.12%+81.70%+110.88% 73.45B
+0.87%+15.32%+56.99%+95.59% 62.99B
+1.71%-1.22%+2.71%+501.29% 28.05B
+4.30%+9.36%+63.29%+25.63% 25.42B
+21.96%+21.98%+1.54%+2.50% 23.3B
+2.28%+5.65%+42.00%-12.34% 19.45B
0.00%-2.78%+247.46%+423.83% 18.16B
+5.83%+5.42%+28.54%+551.76% 16.53B
+2.39%+7.96%+44.96%+157.77% 13.16B
Average +4.20%+5.57%+68.12%+187.94% 28.09B
Weighted average by Cap. +2.71%+6.42%+63.12%+169.46%

Financials

2026 *2027 *
Net sales 26.08M 22.37M 20.89M 19.17M 36.04M 2.49B 36.63M 246M 96.52M 1.25B 97.93M 95.79M 4.13B -
Net income -28.12M -24.12M -22.53M -20.67M -38.86M -2.69B -39.5M -266M -104M -1.35B -106M -103M -4.46B -58.42M -50.12M -46.8M -42.94M -80.74M -5.58B -82.07M -552M -216M -2.8B -219M -215M -9.26B
Net Debt - -
Logo vTv Therapeutics Inc.
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases. Its product pipeline includes TTP399, TTP273, HPP737 and HPP593. The lead product candidate, cadisegliatin (TTP399), is an orally administered, small-molecule, liver-selective glucokinase activator (GKA) that is a potential adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). HPP737 is an orally administered, non-central nervous system (non-CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and offers the potential for an improved tolerability profile and efficacy over commercially available PDE4 inhibitors. TTP273 is an oral, small molecule, glucagon-like peptide 1 (GLP-1) receptor agonist being evaluated for the treatment of type 2 diabetes mellitus. Its product pipeline also includes Azeliragon and HPP3033.
Employees
26
Date Price Change Volume
26-08-19 US$32.90 +4.49% 22,564
26-08-18 US$31.48 +0.54% 70,289
26-08-17 US$31.31 +3.95% 38,770
26-08-14 US$30.12 -2.37% 74,834
26-08-13 US$30.85 -2.93% 35,453
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
32.90USD
Average target price
53.83USD
Spread / Average Target
+63.65%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VTVT Stock